Royal Bank of Canada
STOK icon

Royal Bank of Canada’s Stoke Therapeutics STOK Stock Holding History

Royal Bank of Canada’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Sell
458
-1,165
-72% -$38.2K ﹤0.01% 6022
2025
Q4 		$52K Sell
1,623
-914,163
-100% -$27.5M ﹤0.01% 5534
2025
Q3 		$21.5M Buy
915,786
+771,722
+536% +$13.2M ﹤0.01% 1586
2025
Q2 		$1.64M Buy
144,064
+144,016
+300,033% +$1.37M ﹤0.01% 3467
2025
Q1 		$0 Sell
48
-689
-93% -$6.42K ﹤0.01% 7212
2024
Q4 		$8K Sell
737
-3,566
-83% -$43.8K ﹤0.01% 6417
2024
Q3 		$53K Buy
4,303
+958
+29% +$13.6K ﹤0.01% 5668
2024
Q2 		$45K Buy
3,345
+2,252
+206% +$30.4K ﹤0.01% 5707
2024
Q1 		$14K Sell
1,093
-6,451
-86% -$39.1K ﹤0.01% 6078
2023
Q4 		$40K Buy
7,544
+2,912
+63% +$12.4K ﹤0.01% 6089
2023
Q3 		$18K Buy
4,632
+1,673
+57% +$11K ﹤0.01% 6219
2023
Q2 		$32K Buy
2,959
+1,617
+120% +$17.2K ﹤0.01% 5982
2023
Q1 		$11K Sell
1,342
-3,679
-73% -$33.2K ﹤0.01% 6281
2022
Q4 		$46K Buy
5,021
+4,667
+1,318% +$48.5K ﹤0.01% 5939
2022
Q3 		$5K Buy
354
+147
+71% +$2.34K ﹤0.01% 6749
2022
Q2 		$3K Sell
207
-1,046
-83% -$15.9K ﹤0.01% 6859
2022
Q1 		$27K Sell
1,253
-2,795
-69% -$56K ﹤0.01% 6446
2021
Q4 		$97K Buy
4,048
+2,450
+153% +$58.5K ﹤0.01% 5969
2021
Q3 		$41K Buy
1,598
+291
+22% +$8.11K ﹤0.01% 6282
2021
Q2 		$44K Buy
1,307
+3
+0.2% +$106 ﹤0.01% 6124
2021
Q1 		$51K Buy
1,304
+1,227
+1,594% +$69.9K ﹤0.01% 5868
2020
Q4 		$5K Buy
+77
New +$3.53K ﹤0.01% 6654
2020
Q3 		– Sell
-41
Closed -$1K – 6916
2020
Q2 		$1K Sell
41
-48
-54% -$1.14K ﹤0.01% 6482
2020
Q1 		$2K Sell
89
-759
-90% -$18.8K ﹤0.01% 6331
2019
Q4 		$24K Buy
848
+826
+3,755% +$20.8K ﹤0.01% 5783
2019
Q3 		$0 Buy
+22
New +$613 ﹤0.01% 7089

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Royal Bank of Canada's STOK Position: Q1 2026 in Review

Royal Bank of Canada reduced its Stoke Therapeutics (STOK) stake by 72% in Q1 2026, selling an estimated $38.2K and leaving 458 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #6022.

Royal Bank of Canada first reported a position in STOK in Q3 2019 and has held it in 26 quarters since. The position peaked at $21.5M in Q3 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Royal Bank of Canada held 458 shares of Stoke Therapeutics worth $15K as of Q1 2026.
  • Royal Bank of Canada sold 1,165 Stoke Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Stoke Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6022 holding.
  • Royal Bank of Canada first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • Royal Bank of Canada's Stoke Therapeutics position peaked at $21.5M in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.